Evan Vosburgh, MD
he/him/his
Associate Clinical Professor of Medicine
Research & Publications
Biography
Extensive Research Description
Clinical benign and malignant hematology; neuroendocrine tumor biology; clinical research
Coauthors
Selected Publications
- Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic SystemVosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.
- Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in miceXu EY, Vosburgh E, Wong C, Tang LH, Notterman DA. Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice. Oncotarget 2020, 11: 2718-2739. PMID: 32733644, PMCID: PMC7367653, DOI: 10.18632/oncotarget.27660.
- Two well-differentiated pancreatic neuroendocrine tumor mouse modelsWong C, Tang LH, Davidson C, Vosburgh E, Chen W, Foran DJ, Notterman DA, Levine AJ, Xu EY. Two well-differentiated pancreatic neuroendocrine tumor mouse models. Cell Death & Differentiation 2019, 27: 269-283. PMID: 31160716, PMCID: PMC7206057, DOI: 10.1038/s41418-019-0355-0.
- Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumorsKobayashi S, Contractor T, Vosburgh E, Du YN, Tang LH, Clausen R, Harris CR. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis 2019, 8: 16. PMID: 30796198, PMCID: PMC6386750, DOI: 10.1038/s41389-019-0127-1.
- Abstract 1538: A mouse model that mimics human MEN1 tumor is effective in preclinical neuroendocrine tumor therapeuticsWong C, Clausen R, Tang L, Davidson C, Vosburgh E, Levine A, Xu E. Abstract 1538: A mouse model that mimics human MEN1 tumor is effective in preclinical neuroendocrine tumor therapeutics. Cancer Research 2017, 77: 1538-1538. DOI: 10.1158/1538-7445.am2017-1538.
- Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic SystemVosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2017, 1-12. DOI: 10.1002/9781119000822.hfcm083.
- Abstract 267: Preclinical investigation of the HSP90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human neuroendocrine tumorsWong C, Vosburgh E, Levine A, Proia D, Xu E. Abstract 267: Preclinical investigation of the HSP90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human neuroendocrine tumors. Cancer Research 2016, 76: 267-267. DOI: 10.1158/1538-7445.am2016-267.
- Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016, 7: 30585-30596. PMID: 27105526, PMCID: PMC5058703, DOI: 10.18632/oncotarget.8874.
- Abstract 3185: Complement C5 promotes male bias of pancreatic neuroendocrine tumor metastasisContractor T, Chan C, Kobayashi S, Clausen R, Sun Y, da Silva E, Vosburgh E, Levine A, Tang L, Harris C. Abstract 3185: Complement C5 promotes male bias of pancreatic neuroendocrine tumor metastasis. 2015, 3185-3185. DOI: 10.1158/1538-7445.am2015-3185.
- The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumorsWong C, Laddha S, Tang L, Vosburgh E, Levine A, Normant E, Sandy P, Harris C, Chan C, Xu E. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death & Disease 2014, 5: e1450-e1450. PMID: 25299775, PMCID: PMC4237236, DOI: 10.1038/cddis.2014.396.
- High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and AccuratelyChen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014, 51639. PMID: 25046278, PMCID: PMC4212916, DOI: 10.3791/51639.
- High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and AccuratelyChen W, Wong C, Vosburgh E, Levine A, Foran D, Xu E. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014 DOI: 10.3791/51639-v.
- Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor TherapyWong C, Vosburgh E, Levine AJ, Cong L, Xu EY. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012, 4218. PMID: 22929519, PMCID: PMC3486771, DOI: 10.3791/4218.
- Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor TherapyWong C, Vosburgh E, Levine A, Cong L, Xu E. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012 DOI: 10.3791/4218-v.
- Abstract 4254: Human neuroendocrine Bon 1 cells as a three-dimensional model for the study of human neuroendocrine tumor therapyXu E, Wong C, Levine A, Vosburgh E. Abstract 4254: Human neuroendocrine Bon 1 cells as a three-dimensional model for the study of human neuroendocrine tumor therapy. Cancer Research 2012, 72: 4254-4254. DOI: 10.1158/1538-7445.am2012-4254.
- Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.Gloesenkamp C, Nitzsche B, Lim A, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. International Journal Of Oncology 2012, 40: 1659-67. PMID: 22246317, DOI: 10.3892/ijo.2012.1328.
- A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileumWalsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, DeWan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocrine Related Cancer 2010, 18: 171-180. PMID: 21139019, PMCID: PMC3221459, DOI: 10.1677/erc-10-0248.
- Abstract A215: Hsp90 inhibitor IPI-504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivoLim A, Slocum K, Denyeko I, West K, Palombella V, Fritz C, Vosburgh E, Normant E. Abstract A215: Hsp90 inhibitor IPI-504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo. Molecular Cancer Therapeutics 2009, 8: a215-a215. DOI: 10.1158/1535-7163.targ-09-a215.
- P53 mutations in lymphomas: position mattersLevine AJ, Vosburgh E. P53 mutations in lymphomas: position matters. Blood 2008, 112: 2997-2998. PMID: 18840714, DOI: 10.1182/blood-2008-07-167718.
- Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosisAkpek G, Lenz G, Lee S, Sanchorawala V, Wright D, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo R. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation 2001, 28: 1105-1109. PMID: 11803350, DOI: 10.1038/sj.bmt.1703298.
- Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia AScharrer I, Brackmann H, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000, 6: 614-618. PMID: 11122384, DOI: 10.1046/j.1365-2516.2000.00432.x.
- Safety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia APowell J, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson A, Hurst D. Safety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000, 6: 140-149. PMID: 10792471, DOI: 10.1046/j.1365-2516.2000.00407.x.
- Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home TherapyAbshire T, Brackmann H, Scharrer I, Hoots K, Gazengel C, Powell J, Gorina E, Kellermann E, Vosburgh E. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Thrombosis And Haemostasis 2000, 83: 811-816. PMID: 10896230, DOI: 10.1055/s-0037-1613925.
- Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosisCOMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.
- Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 PatientsComenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.
- Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 PatientsComenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. DOI: 10.1182/blood.v91.10.3662.3662_3662_3670.
- Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 317-24. PMID: 9516917.
- Echocardiographic identification of cardiac amyloidosis patients capable of undergoing intensive treatment with intravenous melphalan therapyMendes L, Reisinger J, Dubrey S, Comenzo R, Vosburgh E, Sanchorawala V, LaValley M, Skinner M, Falk R. Echocardiographic identification of cardiac amyloidosis patients capable of undergoing intensive treatment with intravenous melphalan therapy. Journal Of The American College Of Cardiology 1998, 31: 109. DOI: 10.1016/s0735-1097(98)81120-0.
- Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five PatientsComenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D, Wright D, Falk R, Skinner M. Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients. Blood 1996, 88: 2801-2806. PMID: 8839879, DOI: 10.1182/blood.v88.7.2801.bloodjournal8872801.
- Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.Wright D, Boosalis M, Waraska K, Oshry L, Weintraub L, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Research 1996, 16: 3349-51. PMID: 9042310.
- Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresisComenzo R, Vosburgh E, Weintraub L, Tansan S, Arkin C, Wright D. Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresis. Transfusion 1995, 35: 493-497. PMID: 7770900, DOI: 10.1046/j.1537-2995.1995.35695288768.x.
- Chronic Tension Pneumothorax Mimicking Tension Bullae Use of Video-Assisted Thoracoscopy for DiagnosisKupferschmid J, Carr T, Fonger J, Aldea G, Vosburgh E. Chronic Tension Pneumothorax Mimicking Tension Bullae Use of Video-Assisted Thoracoscopy for Diagnosis. CHEST Journal 1993, 104: 1913-1914. PMID: 8252987, DOI: 10.1378/chest.104.6.1913.
- Rational Intervention in von Willebrand's DiseaseVosburgh E. Rational Intervention in von Willebrand's Disease. Hospital Practice 1993, 28: 31-48. DOI: 10.1080/21548331.1993.11442899.
- Rational intervention in von Willebrand's disease.Vosburgh E. Rational intervention in von Willebrand's disease. Hospital Practice 1993, 28: 31-41, 45-8. PMID: 8450003, DOI: 10.1080/21548331.1993.11442899.
- Excessive Fibrinolysis in Amyloidosis Associated with Elevated Plasma Single-Chain UrokinaseLiebman H, Carfagno M, Weitz I, Berard P, Diiorio J, Vosburgh E, Simms R. Excessive Fibrinolysis in Amyloidosis Associated with Elevated Plasma Single-Chain Urokinase. American Journal Of Clinical Pathology 1992, 98: 534-541. PMID: 1485607, DOI: 10.1093/ajcp/98.5.534.
- Pruritus secondary to hydroxyurea therapy in a woman with polycythemia veraVosburgh E. Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera. American Journal Of Hematology 1992, 41: 70-70. PMID: 1503109, DOI: 10.1002/ajh.2830410120.
- Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.Vosburgh E. Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. Leukemia 1992, 6: 608-10. PMID: 1602800.
- Report of a variant t(1;15;17)(p36;q22;q21.1) in a patient with acute promyelocytic leukemiaOsella P, Wyandt H, Vosburgh E, Milunsky A. Report of a variant t(1;15;17)(p36;q22;q21.1) in a patient with acute promyelocytic leukemia. Cancer Genetics 1991, 57: 201-207. PMID: 1756499, DOI: 10.1016/0165-4608(91)90153-l.
- Isolation From Commercial Aurintricarboxylic Acid of the Most Effective Polymeric Inhibitors of von Willebrand Factor Interaction With Platelet Glycoprotein Ib. Comparison With Other Polyanionic and Polyaromatic PolymersWeinstein M, Vosburgh E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation From Commercial Aurintricarboxylic Acid of the Most Effective Polymeric Inhibitors of von Willebrand Factor Interaction With Platelet Glycoprotein Ib. Comparison With Other Polyanionic and Polyaromatic Polymers. Blood 1991, 78: 2291-2298. PMID: 1932745, DOI: 10.1182/blood.v78.9.2291.2291.
- Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymersWeinstein M, Vosburgh E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers. Blood 1991, 78: 2291-2298. DOI: 10.1182/blood.v78.9.2291.bloodjournal7892291.
- Pathogenesis of idiopathic hypercalciuria: A reviewVosburgh E, Peters T. Pathogenesis of idiopathic hypercalciuria: A review. Journal Of The Royal Society Of Medicine 1987, 80: 34-37. PMID: 3550078, PMCID: PMC1290631, DOI: 10.1177/014107688708000114.